Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention

OncoImmunology

Volumn 3, Issue 4, 2014, Pages

  Raneros, Aroa Baragaño ^a   Suarez Álvarez, Beatriz ^b   López Larrea, Carlos ^a,c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c Section of Nephrology   (Spain)

Author keywords

Exosomes; NKG2D; NKs; Shedding; Soluble NKG2D ligands

Indexed keywords

ANTINEOPLASTIC AGENT; BATIMASTAT; BINDING PROTEIN; DOXORUBICIN; EPIRUBICIN; ERP5 PROTEIN; GI 254023X; GLUCOSE REGULATED PROTEIN 78; GW 280264X; HLA A ANTIGEN; HLA B ANTIGEN; ISOMERASE; LYMPHOCYTE RECEPTOR; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; NATURAL KILLER CELL RECEPTOR NKG2D; NATURAL KILLER GROUP 2 MEMBER D LIGAND; SORAFENIB; UL 16 BINDING PROTEIN 2; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; DOWN REGULATION; DRUG TARGETING; ENZYME INHIBITION; EXOSOME; HUMAN; IMMUNE EVASION; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTERNALIZATION; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR CELL; TUMOR ESCAPE;

EID: 84902579112     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28497     Document Type: Review

References (80)

1. González S, Groh V, Spies T. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 2006; 298:121-38; PMID:16329186; http://dx.doi.org/10.1007/3-540-27743-9_6
2. López-Larrea C, Suárez-Alvarez B, López-Soto A, López-Vázquez A, Gonzalez S. The NKG2D receptor: sensing stressed cells. Trends Mol Med 2008; 14:179-89; http://dx.doi.org/10.1016/j.molmed.2008.02.004; PMID:18353724
3. Eagle RA, Traherne JA, Hair JR, Jafferji I, Trowsdale J. ULBP6/RAET1L is an additional human NKG2D ligand. Eur J Immunol 2009; 39:3207-16; http://dx.doi.org/10.1002/eji.200939502; PMID:19658097
4. Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology 2013; 2:e26097; PMID:24353908; http://dx.doi.org/10.4161/onci.26097
5. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31:413-41; http://dx.doi.org/10.1146/annurevimmunol-032712-095951; PMID:23298206
6. Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S, Schadendorf D, Paschen A. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res 2012; 72:460-71; http://dx.doi.org/10.1158/0008-5472.CAN-11-1977; PMID:22102694
7. Terme M, Borg C, Guilhot F, Masurier C, Flament C, Wagner EF, Caillat-Zucman S, Bernheim A, Turhan AG, Caignard A, et al. BCR/ABL promotes dendritic cell-mediated natural killer cell activation. Cancer Res 2005; 65:6409-17; PMID:16024645; http://dx.doi.org/10.1158/0008-5472.CAN-04-2675
8. Unni AM, Bondar T, Medzhitov R. Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci U S A 2008; 105:1686-91; http://dx.doi.org/10.1073/pnas.0701675105; PMID:18223157
9. Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med 2012; 209:2409-22; http://dx.doi.org/10.1084/jem.20120565; PMID:23166357
10. Fernández-Messina L, Ashiru O, Boutet P, Agüera-González S, Skepper JN, Reyburn HT, Valés-Gómez M. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem 2010; 285:8543-51; http://dx.doi.org/10.1074/jbc.M109.045906; PMID:20080967
11. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2Ddependent natural killer cell cytotoxicity. Cancer Res 2002; 62:6178-86; PMID:12414645
12. Bedel R, Thiery-Vuillemin A, Grandclement C, Balland J, Remy-Martin JP, Kantelip B, Pallandre JR, Pivot X, Ferrand C, Tiberghien P, et al. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. Cancer Res 2011; 71:1615-26; http://dx.doi.org/10.1158/0008-5472.CAN-09-4540; PMID:21257710
13. López-Soto A, Quiñones-Lombraña A, López-Arbesú R, López-Larrea C, González S. Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor. J Biol Chem 2006; 281:30419-30; PMID:16901903; http://dx.doi.org/10.1074/jbc.M604868200
14. Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, Weller M, Friese MA. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006; 129:2416-25; PMID:16891318; http://dx.doi.org/10.1093/brain/awl205
15. Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, Nausch N, Tuettenberg J, Steinle A, Cerwenka A, et al. Interferon-gamma downregulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 2009; 124:1594-604; http://dx.doi.org/10.1002/ijc.24098; PMID:19089914
16. Himmelreich H, Mathys A, Wodnar-Filipowicz A, Kalberer CP. Post-transcriptional regulation of ULBP1 ligand for the activating immunoreceptor NKG2D involves 3′ untranslated region. Hum Immunol 2011; 72:470-8; http://dx.doi.org/10.1016/j.humimm.2011.03.005; PMID:21406206
17. Nachmani D, Lankry D, Wolf DG, Mandelboim O. The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat Immunol 2010; 11:806-13; http://dx.doi.org/10.1038/ni.1916; PMID:20694010
18. Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N, Mandelboim M, Mandelboim O. Human microRNAs regulate stressinduced immune responses mediated by the receptor NKG2D. Nat Immunol 2008; 9:1065-73; http://dx.doi.org/10.1038/ni.1642; PMID:18677316
19. Yadav D, Ngolab J, Lim RS, Krishnamurthy S, Bui JD. Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gammainduced microRNA. J Immunol 2009; 182:39-43; PMID:19109132; http://dx.doi.org/10.4049/jimmunol.182.1.39
20. Tsukerman P, Stern-Ginossar N, Gur C, Glasner A, Nachmani D, Bauman Y, Yamin R, Vitenshtein A, Stanietsky N, Bar-Mag T, et al. MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res 2012; 72:5463-72; http://dx.doi.org/10.1158/0008-5472.CAN-11-2671; PMID:22915757
21. Andresen L, Skovbakke SL, Persson G, Hagemann-Jensen M, Hansen KA, Jensen H, Skov S. 2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation. J Immunol 2012; 188:1847-55; http://dx.doi.org/10.4049/jimmunol.1004085; PMID:22227571
22. Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, Carosella ED, LeMaoult J. Trogocytosisbased generation of suppressive NK cells. EMBO J 2007; 26:1423-33; PMID:17318190; http://dx.doi.org/10.1038/sj.emboj.7601570
23. Roda-Navarro P, Vales-Gomez M, Chisholm SE, Reyburn HT. Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. Proc Natl Acad Sci U S A 2006; 103:11258-63; PMID:16849432; http://dx.doi.org/10.1073/pnas.0600721103
24. Domaica CI, Fuertes MB, Rossi LE, Girart MV, Avila DE, Rabinovich GA, Zwirner NW. Tumourexperienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands. EMBO Rep 2009; 10:908-15; http://dx.doi.org/10.1038/embor.2009.92; PMID:19498463
25. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169:4098-102; PMID:12370336; http://dx.doi.org/10.4049/jimmunol.169.8.4098
26. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102:1389-96; PMID:12714493; http://dx.doi.org/10.1182/blood-2003-01-0019
27. Hilpert J, Grosse-Hovest L, Grünebach F, Buechele C, Nuebling T, Raum T, Steinle A, Salih HR. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012; 189:1360-71; http://dx.doi.org/10.4049/jimmunol.1200796; PMID:22730533
28. Nückel H, Switala M, Sellmann L, Horn PA, Dürig J, Dührsen U, Küppers R, Grosse-Wilde H, Rebmann V. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 2010; 24:1152-9; http://dx.doi.org/10.1038/leu.2010.74; PMID:20428196
29. Huergo-Zapico L, Gonzalez-Rodriguez AP, Contesti J, Gonzalez E, López-Soto A, Fernandez-Guizan A, Acebes-Huerta A, de Los Toyos JR, Lopez-Larrea C, Groh V, et al. Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding. Cancer Immunol Immunother 2012; 61:1201-10; http://dx.doi.org/10.1007/s00262-011-1195-z; PMID:22215138
30. Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, Aguilar-Lemarroy A, Troyo-Sanroman R, Bravo-Cuellar A, Delgado-Rizo V, et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 2008; 8:16; http://dx.doi.org/10.1186/1471-2407-8-16; PMID:18208618
31. Kumar V, Yi Lo PH, Sawai H, Kato N, Takahashi A, Deng Z, Urabe Y, Mbarek H, Tokunaga K, Tanaka Y, et al. Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma. PLoS One 2012; 7:e44743; PMID:23024757; http://dx.doi.org/10.1371/journal.pone.0044743
32. Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J, Sun W. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol 2011; 28:466-74; http://dx.doi.org/10.1007/s12032-010-9480-9; PMID:20354827
33. Chung HW, Lim JB. Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma. Cancer Sci 2011; 102:1673-9; http://dx.doi.org/10.1111/j.1349-7006.2011.01989.x; PMID:21615621
34. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004; 6:558-68; PMID:15548365; http://dx.doi.org/10.1593/neo.04316
35. Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 2009; 15:5208-15; http://dx.doi.org/10.1158/1078-0432.CCR-09-0886; PMID:19671853
36. Del Toro-Arreola S, Arreygue-Garcia N, Aguilar-Lemarroy A, Cid-Arregui A, Jimenez-Perez M, Haramati J, Barros-Nuñez P, Gonzalez-Ramella O, Del Toro-Arreola A, Ortiz-Lazareno P, et al. MHC class I-related chain A and B ligands are differentially expressed in human cervical cancer cell lines. Cancer Cell Int 2011; 11:15; http://dx.doi.org/10.1186/1475-2867-11-15; PMID:21631944
37. Yamaguchi K, Chikumi H, Shimizu A, Takata M, Kinoshita N, Hashimoto K, Nakamoto M, Matsunaga S, Kurai J, Miyake N, et al. Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients. Cancer Sci 2012; 103:1405-13; http://dx.doi.org/10.1111/j.1349-7006.2012.02330.x; PMID:22587355
38. Tamaki S, Kawakami M, Ishitani A, Kawashima W, Kasuda S, Yamanaka Y, Shimomura H, Imai Y, Nakagawa Y, Hatake K, et al. Soluble MICB serum levels correlate with disease stage and survival rate in patients with oral squamous cell carcinoma. Anticancer Res 2010; 30:4097-101; PMID:21036725
39. Wu BJ, Li WP, Qian C, Ding W, Zhou ZW, Jiang H. Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients. Tumour Biol 2013; 34:565-9; http://dx.doi.org/10.1007/s13277-012-0582-1; PMID:23150178
40. Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005; 43:1013-20; PMID:16168521; http://dx.doi.org/10.1016/j.jhep.2005.05.026
41. Rebmann V, Schütt P, Brandhorst D, Opalka B, Moritz T, Nowrousian MR, Grosse-Wilde H. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol 2007; 123:114-20; PMID:17218152; http://dx.doi.org/10.1016/j.clim.2006.11.007
42. Cao W, Xi X, Hao Z, Li W, Kong Y, Cui L, Ma C, Ba D, He W. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. J Biol Chem 2007; 282:18922-8; PMID:17470428; http://dx.doi.org/10.1074/jbc.M702504200
43. Eagle RA, Flack G, Warford A, Martínez-Borra J, Jafferji I, Traherne JA, Ohashi M, Boyle LH, Barrow AD, Caillat-Zucman S, et al. Cellular expression, trafficking, and function of two isoforms of human ULBP5/RAET1G. PLoS One 2009; 4:e4503; http://dx.doi.org/10.1371/journal.pone.0004503; PMID:19223974
44. Noël A, Gutiérrez-Fernández A, Sounni NE, Behrendt N, Maquoi E, Lund IK, Cal S, Hoyer-Hansen G, López-Otín C. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol 2012; 3:140; http://dx.doi.org/10.3389/fphar.2012.00140 ; PMID:22822400
45. Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, McGowan PM. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics 2011; 8:9; http://dx.doi.org/10.1186/1559-0275-8-9; PMID:21906355
46. Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008; 68:6368-76; http://dx.doi.org/10.1158/0008-5472.CAN-07-6768; PMID:18676862
47. Sun D, Wang X, Zhang H, Deng L, Zhang Y. MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int 2011; 35:569-74; http://dx.doi.org/10.1042/CBI20100431; PMID:21143201
48. Yamanegi K, Yamane J, Kobayashi K, Ohyama H, Nakasho K, Yamada N, Hata M, Fukunaga S, Futani H, Okamura H, et al. Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells. Oncol Rep 2012; 28:1585-90; http://dx.doi.org/10.3892/or.2012.1981; PMID:22923031
49. Kim ES, Kim MS, Moon A. TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 2004; 25:1375-82; PMID:15492828
50. Liu G, Atteridge CL, Wang X, Lundgren AD, Wu JD. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J Immunol 2010; 184:3346-50; http://dx.doi.org/10.4049/jimmunol.0903789; PMID:20208009
51. Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Fürst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH, et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Int J Cancer 2013; 133:1557-66; http://dx.doi.org/10.1002/ijc.28174; PMID:23526433
52. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR, Graham CH. Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res 2011; 71:7433-41; http://dx.doi.org/10.1158/0008-5472.CAN-11-2104; PMID:22006996
53. Adrain C, Zettl M, Christova Y, Taylor N, Freeman M. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science 2012; 335:225-8; http://dx.doi.org/10.1126/science.1214400; PMID:22246777
54. McIlwain DR, Lang PA, Maretzky T, Hamada K, Ohishi K, Maney SK, Berger T, Murthy A, Duncan G, Xu HC, et al. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science 2012; 335:229-32; http://dx.doi.org/10.1126/science.1214448; PMID:22246778
55. Siggs OM, Xiao N, Wang Y, Shi H, Tomisato W, Li X, Xia Y, Beutler B. iRhom2 is required for the secretion of mouse TNFα. Blood 2012; 119:5769-71; http://dx.doi.org/10.1182/blood-2012-03-417949; PMID:22550345
56. Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, Hayashi N. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 2010; 51:1264-73; http://dx.doi.org/10.1002/hep.23456; PMID:20099300
57. Kohga K, Tatsumi T, Tsunematsu H, Aono S, Shimizu S, Kodama T, Hikita H, Yamamoto M, Oze T, Aketa H, et al. Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma. Cancer Immunol Immunother 2012; 61:1425-32; PMID:22302133; http://dx.doi.org/10.1007/s00262-012-1208-6
58. Wu JD, Atteridge CL, Wang X, Seya T, Plymate SR. Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res 2009; 15:632-40; http://dx.doi.org/10.1158/1078-0432.CCR-08-1305; PMID:19147769
59. Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Ohyama H, Nakasho K, Yamada N, Hata M, Fukunaga S, Futani H, et al. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fasand NK cell-mediated cell death. Int J Oncol 2012; 41:83-91; http://dx.doi.org/10.3892/ijo.2012.1438; PMID:22576685
60. Duan X, Mao X, Sun W. ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells. Mol Med Rep 2013; 7:991-7; http://dx.doi.org/10.3892/mmr.2013.1272; PMID:23314034
61. Boutet P, Agüera-González S, Atkinson S, Pennington CJ, Edwards DR, Murphy G, Reyburn HT, Valés-Gómez M. Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 2009; 182:49-53; PMID:19109134; http://dx.doi.org/10.4049/jimmunol.182.1.49
62. Agüera-González S, Gross CC, Fernández-Messina L, Ashiru O, Esteso G, Hang HC, Reyburn HT, Long EO, Valés-Gómez M. Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding. Eur J Immunol 2011; 41:3667-76; PMID:21928280; http://dx.doi.org/10.1002/eji.201141645
63. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66:2520-6; PMID:16510567; http://dx.doi.org/10.1158/0008-5472.CAN-05-2520
64. Hedlund M, Nagaeva O, Kargl D, Baranov V, Mincheva-Nilsson L. Thermal- and oxidative stress causes enhanced release of NKG2D ligandbearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One 2011; 6:e16899; http://dx.doi.org/10.1371/journal.pone.0016899; PMID:21364924
65. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115:3719-27; PMID:12235282; http://dx.doi.org/10.1242/jcs.00063
66. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010; 20:161-8; http://dx.doi.org/10.1016/j.semcancer.2010.05.002; PMID:20470890
67. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010; 1803:55-71; http://dx.doi.org/10.1016/j.bbamcr.2010.01.003; PMID:20080133
68. Zhang LH, Zhang X. Roles of GRP78 in physiology and cancer. J Cell Biochem 2010; 110:1299-305; http://dx.doi.org/10.1002/jcb.22679; PMID:20506407
69. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH, Strong RK, Groh V, Spies T. Disulphide-isomerase-enabled shedding of tumourassociated NKG2D ligands. Nature 2007; 447:482-6; PMID:17495932; http://dx.doi.org/10.1038/nature05768
70. Zocchi MR, Catellani S, Canevali P, Tavella S, Garuti A, Villaggio B, Zunino A, Gobbi M, Fraternali-Orcioni G, Kunkl A, et al. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood 2012; 119:1479-89; http://dx.doi.org/10.1182/blood-2011-07-370841; PMID:22167753
71. Zhang HG, Grizzle WE. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res 2011; 17:959-64; http://dx.doi.org/10.1158/1078-0432.CCR-10-1489; PMID:21224375
72. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes downmodulate NKG2D expression. J Immunol 2008; 180:7249-58; PMID:18490724; http://dx.doi.org/10.4049/jimmunol.180.11.7249
73. Viaud S, Terme M, Flament C, Taieb J, André F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T, et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One 2009; 4:e4942; http://dx.doi.org/10.1371/journal.pone.0004942; PMID:19319200
74. Ashiru O, Boutet P, Fernández-Messina L, Agüera-González S, Skepper JN, Valés-Gómez M, Reyburn HT. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 2010; 70:481-9; http://dx.doi.org/10.1158/0008-5472.CAN-09-1688; PMID:20068167
75. Ashiru O, López-Cobo S, Fernández-Messina L, Pontes-Quero S, Pandolfi R, Reyburn HT, Valés-Gómez M. A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008. Biochem J 2013; 454:295-302; http://dx.doi.org/10.1042/BJ20130194; PMID:23772752
76. Xu X, Rao GS, Groh V, Spies T, Gattuso P, Kaufman HL, Plate J, Prinz RA. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabineinduced MICA/B expression. BMC Cancer 2011; 11:194; http://dx.doi.org/10.1186/1471-2407-11-194; PMID:21605422
77. Morisaki T, Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, Ogino T, Nagamatsu I, Katano M. Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system. Anticancer Res 2011; 31:2505-10; PMID:21873167
78. Kohga K, Takehara T, Tatsumi T, Miyagi T, Ishida H, Ohkawa K, Kanto T, Hiramatsu N, Hayashi N. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res 2009; 69:8050-7; http://dx.doi.org/10.1158/0008-5472.CAN-09-0789; PMID:19826051
79. Yamanegi K, Yamane J, Kobayashi K, Ohyama H, Nakasho K, Yamada N, Hata M, Fukunaga S, Futani H, Okamura H, et al. Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells. Oncol Rep 2012; 28:1585-90; http://dx.doi.org/10.3892/or.2012.1981; PMID:22923031
80. Chávez-Blanco A, De la Cruz-Hernández E, Domínguez GI, Rodríguez-Cortez O, Alatorre B, Pérez-Cárdenas E, Chacón-Salinas R, Trejo-Becerril C, Taja-Chayeb L, Trujillo JE, et al. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol 2011; 39:1491-9; http://dx.doi.org/10.3892/ijo.2011.1144; PMID:21805029